Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, noviembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Iovance Biotherapeutics Inc
IOVA
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$6.90
-0.41
-5.61%
al cierre: Nov 20, 4:00 PM EST
$6.99
0.0862
1.25%
After hour: 7:59 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Iovance Biotherapeutics Financials
Iovance Biotherapeutics (IOVA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $410.000M-$420.000M vs $416.263M Est
Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $410.000 million-$420.000 million to $410.000 million-$420.000 million vs $416.263 million estimate.
Benzinga Newsdesk
PRO
Iovance Biotherapeutics Q3 EPS $(0.05) Beats $(0.09) Estimate, Sales $121.469M Beat $115.982M Estimate
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 37.5 percent. This is a 80 percent increase over losses of $(0.25) per share
Benzinga Newsdesk
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
Vandana Singh
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
Avi Kapoor
PRO
Iovance Raises FY2026 Total Revenue Guidance From $350M-$370M To $410M-$420M
Benzinga Newsdesk
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.
Evette Mitkov